From an evidence-based perspective, proof of the efficacy of integrative cancer therapies is sorely needed. Evidence-based medicine is concerned with the careful gathering and interpretation of research to solve a medical problem. The Evidence-Based Medicine Working Group has defined it as "the process of systematically finding, appraising, and using contemporaneous research findings as the basis for clinical decisions." 1 This definition harks back to the timehonored process of combining clinical expertise and patient preferences with the best available evidence from the medical literature concerning treatment safety and effectiveness.
Physicians are duty-bound to assist their patients in making informed choices based on the best available evidence. Nonetheless, the evidence-based approach to cancer medicine is an arduous challenge, one made no less simple by the astounding diversity and heterogeneity of malignant diseases. This challenge becomes magnified in the context of integrative oncology, in part because such a wide variety of therapeutic combinations may apply to each cancer, depending on disease characteristics and the clinical situation. No definitive consensus exists, as yet, on the use of integrative treatment protocols or their standardization within the oncologic setting. The protocols themselves appear to be in a constant state of flux, reflecting the incipient nature of this emerging medical discipline.
Randomized controlled trials (RCTs) remain the gold standard for establishing treatment efficacy. Some physicians are content to dismiss integrative cancer therapies that have not been evaluated with RCTs. The assumption is that RCTs represent the sole yardstick with which to measure the true value of a therapeutic option. The vast majority of decisions relating to the management of cancer patients, however, are not based on randomized trials. Some research indicates that only between 20% and 50% of the decisions made in conventional medicine have been substantiated through clinical trials. 2 Recent reviews have suggested that RCTs are not always more informative than observational studies. 3, 4 In particular, they are not the best sources for answering questions about diagnosis, prognosis, or harm. Cohort and case-control studies often serve better in these capacities. Some RCTs, moreover, are seriously flawed, due to less-than-optimal interventions (eg, in the case of supplements, the use of inadequate dosages or poor-quality agents) or due to small study size, resulting in inadequate statistical power.
Furthermore, despite the urgings of those in the research communities, not all community clinics are anxious to participate as sites in clinical trials, leading to difficulties in recruitment of patients to large-scale trials. Adherence to a rigid treatment protocol is among the main reasons many oncologists decline participation in RCTs. 5 In the real world of clinical medicine, cytotoxic treatment protocols are constantly adjusted in terms of drug combinations and dosages because the physician must exercise a considerable degree of clinical judgment in each case. Clinicians usually make recommendations on a case-bycase basis guided by the results of a highly diverse body of evidence as well as expert opinion. It may be argued that the strict or uniform application of evidencebased medicine, while an understandable goal, remains more of an ideal than a practical reality. Evidencebased integrative cancer medicine, in which a diverse and shifting array of complementary treatments is employed alongside the clinical judgment needed in conventional medicine, is even further from practical reality.
There are also several issues inherent to the nature and practice of integrative cancer care that pose challenges to the use of clinical trial testing. First, integrative treatment approaches are often highly individualized and attempt to respond to patients' specific needs. Second, these approaches are often holistic, taking into account many facets of a patient's life, including quality-of-life concerns. Third, along similar lines, outcomes of integrative medicine are often subjective as well as objective (ie, survival time). Fourth, placebo effects, nonspecific effects, and the psychological (emotional as well as psychospiritual) influence of the physician are frequently recognized as part of the treatment effect. Fifth, the diversity of agents used across different integrative approaches, and even within single integrative approaches, means that a full understanding of integrative cancer medicine may simply be impractical, due to the number of trials that would have to take place. A fair evaluation of integrative therapies requires sensitivity toward these issues and may call for adjustments in the way research is carried out in this area. Do these problems mean that RCTs are not, in fact, the best way to research integrative cancer care?
This question and the other questions we posed to participants in this Point-Counterpoint raise some deep and perplexing issues. One could conceivably construct an entire symposium around each question. We asked each participant to view the questions as an invitation to enter into a conversation on this complex subject. The purpose of this roundtable discussion was to stimulate a brainstorming process, debating the best ways to carry out research on integrative cancer therapies in the current setting of limited funding and limited numbers of qualified investigators in this field.
The investigators we asked to participate in this discussion are both qualified and diverse. Adrian Sandra Dobs, MD, MHS, is a professor of medicine and oncology, vice chair of the Department of Medicine for Clinical Research, and the director of the Johns Hopkins University School of Medicine Clinical Trials Unit. Dr Dobs received her undergraduate degree at Cornell University, medical school training at Albany Medical College, and clinical training in internal medicine at Montefiore Hospital, Albert Einstein College of Medicine, in New York City. She came to Johns Hopkins for a fellowship in endocrinology and metabolism where she also received a master's in health sciences degree in clinical epidemiology from the Johns Hopkins School of Public Health. Dr Dobs is presently an active investigator in the field of sex hormone disorders. She is a dedicated clinical investigator who has published extensively in HIV-related endocrinopathies and risks and benefits of testosterone replacement therapies.
Dr Dobs sits on the National Institutes of Health (NIH) Study Section for General Clinical Research Centers. In addition to extensive funding from the private sector, she presently has 2 RO1s and a Center Grant. She has developed the Johns Hopkins School of Medicine Clinical Trials Unit, where she oversees a team of individuals dedicated to facilitating clinical research within an academic medical center environment. She was recently awarded an NIH $8 million grant to direct the Johns Hopkins Complementary and Alternative Medicine Cancer Center. In addition to her research success, Dr Dobs maintains a thriving clinical practice at Johns Hopkins and is an active teacher in both endocrinology and general medicine.
Andrea J. Cohen, MD, FRCPC, is an associate professor of medicine at the University of Colorado Health Sciences Center and the director of the Complementary and Alternative Medicine Research Program at the University of Colorado Cancer Center. She is the principal investigator on a P30 grant in complementary and alternative medicine (CAM) and cancer from the National Cancer Institute. Her laboratory conducts state-of-the-art clinical, translational, and basic research. Dr Cohen has conducted traditional molecular cancer research including topics in lung cancer on peptides, peptidases, endothelin autocrine loop, and methylation. Dr Cohen's CAM interests include Indian and Chinese medicine as well as mindbody medicine. She is the principal investigator on several CAM randomized trials, including the clinical and biological effects of guided imagery for lymphoma and leukemia in bone marrow transplant patients and acupuncture for the side effects of chemotherapy in breast cancer patients. In addition, her lab group is performing preclinical work in homeopathy and natural products. Dr Cohen is a pulmonologist and internist; in addition, she is board certified in holistic medicine. She lectures internationally on topics in integrative medicine and CAM research methodology.
Suzanne M. Hess, PhD, is an assistant professor in the Department of Radiation Oncology at Wake Forest University School of Medicine (WFUSM) in WinstonSalem, North Carolina. Her research interests focus on novel cancer therapeutics, radiation sensitization, and CAM. Her CAM research focuses on 2 areas: energy-based medicine and therapeutic-grade essential oils. She is looking at the effect of Reiki using a mouse colon cancer xenograft model. A concept has also been proposed to the Wake Forest University This Point-Counterpoint will be presented as a series of questions, each followed by the responses of all of the panelists to that question. After the panelists' responses to all the questions have been presented, a summary and discussion by the first author of the Point-Counterpoint will appear.
Question 1.
Integrative cancer therapy has been defined as cancer care that combines conventional medicine with the rational use of complementary and alternative medicine (CAM) modalities. It has been argued by some that integrative therapies cannot be adequately studied with randomized controlled trials. Problems that have been raised with the study of these are the inability to measure endpoints considered important by CAM practitioners and the practice of individualizing therapeutic protocols employed in integrative medicine. Please discuss the suitability of randomized trials for the evaluation of integrative therapies. For example, how would you address the problems of extrascientific endpoints and individualization?
Hess: I do not believe that the integrative treatment of cancer can be adequately studied with randomized controlled trials (RCTs). There are several issues in general that need to be addressed when talking about applying the RCT model to the study of integrative therapies. First, many RCTs do not lend themselves readily to individualized treatment, which is a fundamental premise of many CAM approaches that involve the integration of conventional and complementary therapies. Second, only a small percentage of individuals, perhaps 3% to 4%, actually consents to taking part in RCTs. Therefore, recruitment becomes an issue, and completion of CAM trials often does not occur in a timely manner, particularly in the case of advanced cancers. Third, recruitment becomes even more difficult when trying to recruit for an intervention that is perhaps considered fringe or unorthodox by most of the medical community and lay population. Fourth, medical personnel who are poorly informed about a particular CAM intervention (this is usually not something they learned about in medical school) may tend to instruct participants poorly, resulting in improper implementation of the intervention. Along these lines, subtle biases on the part of the study's personnel may inadvertently discourage adherence to the study protocol, resulting in a diminution of the true effect. Such untoward effects may be more pronounced when a study is conducted in an effort to disprove another study's findings. The endpoints typically used in cancer research include survival, tumor response, reduction of side effects from the treatment, and biomarker changes. Many CAM interventions not only may affect these conventional endpoints but also may result in improved functionality and quality of life. If a particular intervention improves the patient's quality of life but does not improve survival compared to the standard treatment group, do we consider this a failure or a success? Most CAM practitioners would consider it a success if the patient showed improvement on the mental, emotional, or spiritual levels, as well as on the physical level measured in terms of the conventional endpoints alluded to above. Integrative medicine therefore challenges us to think about whether we need to change the paradigm of what we think is the gold standard and how we think about healing/cure. Cohen: RCTs have long been the gold standard for studying any form of treatment, conventional or alternative. Within the RCT model, the medical community believes that internal validity is maintained. Most physicians and scientists are therefore quite comfortable with the findings from RCTs. Nonetheless, these studies are expensive and not always appropriate for CAM studies, and the results cannot be generalized. They are excellent for measuring specific effects but may not capture synergistic or nonspecific effects. In addition, it may be hard to get patients to agree to be randomized, and patients and physicians may feel that it is unethical or unacceptable to withhold treatment and thus decline participation.
There is a tendency within the medical establishment to assume that the findings obtained from RCTs are more conducive to information that can and should be translated into clinical practice. But this is an area of some controversy. First, because the study groups in randomized trials are typically homogeneous (eg, 70-kg white men between the ages of 20 and 50), the results are not always generalizable to the population at large. This is a problem with all RCTs, whether they involve conventional drugs alone or integrative therapies.
Second, the modalities examined in randomized trials are employed in a manner that diverges markedly from actual clinical practice. For example, acupuncturists prefer to treat complaints on an individual basis. An acupuncturist will take a patient's history and pulse diagnosis at each visit and use this information to plan the patient's treatment. RCTs, however, use acupoints that are known to be useful for many medical problems, such as asthma and peripheral neuropathy, and then design studies using a set panel of points to ensure that the study protocol is reproducible. Some of these set point studies, though, have yielded null results, leading reviewers to wrongly conclude that acupuncture is ineffective for that condition. There are times when using a set protocol for acupuncture in a randomized trial may be appropriate, such as in cases in which the cause of the problem is known, such as for chemotherapy side effects.
The problems of extrascientific endpoints and individualization are an area of active discussion. We need to better define the benefits that patients derive from integrative therapies. If the endpoint is a typical endpoint such as heart rate or blood pressure following meditation, then it is appropriate to use these scientific endpoints. Many of the CAM endpoints, however, are less tangible. We need to give a great deal of thought to these endpoints and see if existing questionnaires cover the endpoints that CAM modifies. If not, we need to prepare novel quality-oflife tools to measure unique endpoints in CAM trials, then we need to validate these new tools. At a recent whole-systems research workshop in Vancouver in 2002, attendees mentioned that CAM therapies have unique outcomes such as alleviation of "stuckedness," defined as the quality-of-life change that occurs when people do the things in their life that they were stuck on (ie, quitting smoking) as the task seemed overwhelming. Becoming unstuck is important healthwise because it allows patients to initiate and stick to positive health behaviors, such as diet, exercise, and stopping smoking.
Endpoints should include detailed spiritual endpoints. In addition, at the whole-systems research workshop mentioned above, workshop attendees discussed that patients be interviewed and new endpoints developed. Endpoints should also be related to patient-held values and the outcomes that cause them to continue to seek CAM and pay for it out of pocket. There is active work being done in this area. For unique endpoints, we may be able to use visual analogue scale for unique endpoints such as inertia, boundaries, and centeredness.
Last, within the RCT framework, it is sometimes difficult to design appropriate treatment and control groups. Due to design issues that are often based on practicality or budget, several CAM trials have had treatment and sham groups, but without a true control group. The control group is important in part because it controls for the nonspecific effects of the practitioner. In some studies, for example, both treatment and sham groups improved, but there was no significant difference between the groups. Perhaps the clinicians or therapists in these studies conferred nonspecific effects on both groups of patients. Removing bias in an RCT could affect results in a CAM research study as nonspecific effects may be critically important to the therapeutic outcome. Vickers: In my view, this question is out of date. It was discussed at length in the 1980s and 1990s, and the arguments against the appropriate use of randomized trials were found to be baseless (this debate has been summarized in 2 papers 6,7 ). One key point is that study design cannot be discussed independently of the question being asked in research. Randomized trials are a good way of deciding whether a treatment does more good than harm, an important question to ask about any therapy. There is absolutely no reason why treatment individualization cannot be incorporated in randomized trials (it commonly is), and similarly, there is no constraint on the type of endpoints that can be assessed. Randomized trials are not appropriate for other types of questions: as examples from my own research, how many women with breast cancer use CAM? What advice do health stores give to a patient presenting with headache? By the way, I am not particularly interested in the endpoints considered important by CAM practitioners; I am interested in what patients consider important. I am also interested in endpoints considered important by oncologists (eg, response) because these have generally been shown to correlate with outcomes relevant to patients (eg, pain, survival). Burns: We can approach this issue in several ways. I think it is important to begin with a distinction concerning the types of problems we are trying to solve. When there is a relatively simple health problem, such as shoulder pain, researchers will typically focus on a single-modality treatment, such as acupuncture. A dual-arm clinical trial can be designed to study this. Even in this simplistic framework, however, the kind of information generated is often not relevant to realworld circumstances and cannot be compared to the real-world situation in which acupuncture is only one of several modalities employed. When you have a systemic illness such as cancer, it becomes very difficult to evaluate a system of medicine-in this case, the integrative approach to cancer care-that is used in multifaceted ways with many modalities and try to separate out the effects of those modalities. When you apply the modern research model to the study of herbal medicine, you begin to notice that it invariably leads to drug development. The research is not really aimed at discerning how herbs are used traditionally or how they are currently used in the community. It is not designed to determine how herbs are woven into a more comprehensive treatment plan, one in which herbs may have an integral part, but one in which they may support the effects of other modalities, including conventional treatments. As a result, those studies that tend to view herbs within a kind of single-agent, pharmaceutical framework may not be reflecting the true value of herbs, or they may uncover an effect of herbal agents that may neither be true nor relevant. In the trials that evaluate individual modalities such as acupuncture or a single herb or herbal formula, the comparison arm is often very poor. Moreover, the study leaves out a critical piece, and that is diagnosis. We are using Western diagnoses to determine a Chinese medicine treatment. When we do that, we have abrogated our responsibility to retain the underlying logic on which the Chinese medical system is predicated. We need to use a traditional Chinese diagnostic system before putting patients in the treatment arm because the diagnosis dictates the treatment, and in Chinese medicine (as in homeopathy), this relationship is highly individualized. Dobs: The 2 fundamental questions we have to ask ourselves when evaluating CAM or integrative therapies are as follows. First, what is the intervention, and how do we standardize the intervention, particularly when it involves many different variables (eg, not just nutrients or botanicals, but meditation, self-hypnosis, or exercise regimens as well)? Second, what outcome measures are to be included in our investigation? Are we interested in a disease state, a hormone level, a laboratory assay, a quality-of-life index? We need to keep in mind that the problem of studying multiple interventions and multiple endpoints is not unique to studies of integrative or CAM therapies. Many CAM investigators and practitioners have spoken of the difficulty of documenting multiple interventions and outcomes. This more complex focus, however, is more compatible with what we see in the clinical setting. In real life, traditional Chinese medicine (TCM) does not involve simply giving a single herb and seeing what happens. In real life, the Chinese herbs are combined and tailored to the individual patient to provide the right balance for that individual; in most cases, the herbs are combined with other modalities such as acupuncture, qigong exercise, or relaxation techniques. The integrative medical approach frequently entails multiple interventions, although a single intervention may also be used in some cases.
In many ways, moreover, this issue of multiple interventions also applies to the treatment of classical medical conditions, such as diabetes. The treatment and management of diabetes mellitus does not just entail insulin monitoring and administration but also nutrition, exercise, and other health care practices and modifications. Many recent clinical trials have examined the total intervention for the management of diabetes, rather than one specific change in a variable. The problem being addressed in the evaluation of CAM therapies is analogous to any approach to a medical condition that requires a broad set of treatments or interventions. Whenever feasible, multiple outcome measures should be evaluated as well. In this context, CAM studies can be performed in the same rigorous fashion needed for studying conventional treatment approaches.
Quality-of-life studies have great potential because there is less bureaucratic red tape involved and thus more freedom intrinsic to the pursuit of such studies. Perhaps the integrative treatment approach has little or no impact on the course of disease, but we know of many instances in which it has been shown to improve quality of life; the patient feels better, even though he or she still has the same disease state and mortality outcome. Perhaps the patient has better functional outcomes, such as improved sleep, sexual function, and emotional well-being. Such quality-of-life outcomes are an essential part of the challenge of doing research on integrative treatment approaches.
Proponents of RCTs argue that we need to maintain uniformity or homogeneity within the intervention. The reality of cancer care, however, is that oncologists are constantly having to adjust conventional drug regimens for each individual patient in response to treatment situations as they arise; for example, when a drug's toxicity is excessive or when tumors do not respond to a particular regimen. Of course, as many clinical investigators acknowledge, minimizing the variability within an intervention is necessary to maintain the quality of the data; otherwise, you would not be able to draw valid or consistent conclusions about the group under study. Nonetheless, compromises can be made and may be acceptable within a given treatment paradigm to reflect clinical reality. As an example, consider the situation in which the physician elects to escalate a dose to elicit a larger treatment response. This situation can apply to nutrients and botanicals as much as it does to chemotherapy drugs. You start at one level but have the freedom to escalate the dose. In other words, there are ways of building into the study some sense of individualization, without destroying the integrity of the underlying study design. This has been done with clinical trials of homeopathy.
Question 2.
Integrative medicine relies on a wide variety of CAM therapies. Each of these therapies individually merits scientific evaluation on its own, but integrative medicine as a whole also merits such trial testing. The expense of conducting well-designed randomized trials is immense, as is the patient-driven demand for information on the wide variety of integrative therapies. How can we best allocate financial resources in developing a useful body of information on integrative cancer therapies? Please consider the relative value of large randomized trials, small-scale exploratory studies, population-based studies of use of CAM therapies by patients, and other research models currently in use.
Hess: Financial resources should be allocated in several areas of CAM development. Web-based dissemination of information on funding can occur through several groups including the government (National Institutes of Health [NIH]/National Cancer Institute [NCI]), nonprofit groups specializing in cancer research (American Cancer Society, Komen Foundation), and national organizations of health care providers who specialize in the treatment of CAM programs. Educational information on CAM also needs to be developed by the NCI that can be distributed in hard copy in multiple languages at cancer centers and oncologist offices. Financial resources should be spent on the sponsorship of meetings that are CAM based and those that are not to include information to professionals of cancer-focused groups and cooperative groups. More continuing education programs should also be supported that will educate health care professions and allied health care workers on CAM. Because RCTs are extremely expensive, it behooves the research community to make sure that any money allocated for these trials is money well spent. To this end, the trial should be expertly conceived and designed. Some of the clinical trials on CAM have been inadequately powered, mainly due to small numbers of individuals participating in the trial. Others have not followed the intervention indicated by clinical experience or by less expensive, nonrandomized studies. Given the time, energy, and financial outlays for conducting these difficult and expensive trials, one would hope that Institutional Review Board committees will approve only those trials that have adequate statistical power as well as a solid commitment to delivering CAM interventions of the highest quality. This will give us more confidence as to whether the specific intervention has efficacy, and it will prevent much unnecessary spending. Cohen: It is important to perform CAM research in a carefully planned manner and to perform the research in stages. There are many reasons for carrying out research in a very controlled, meticulous, systematic manner. First of all, there are many types of natural products and modalities out there. Some may be ineffective and therefore a waste of time and money; some of these may in fact be dangerous for the cancer patient. CAM research should be aimed at determining how integrative therapies interact with conventional medicines and how they may modify the side-effect profile. This knowledge will assist in determining whether they should become incorporated into conventional cancer care. Clinical trial research is expensive and timeconsuming. Therefore, the CAM research community needs to come together to prioritize areas of research. For example, we could have more consensus-making conferences to determine which therapies can be studied independently or on a stand-alone basis. Acupuncture, the subject of a recent NIH consensus conference, may be such a therapy. We could use these conferences to recruit practitioners of integrative cancer care to perform outcomes studies. We can also ask them to pull together data prospectively in longitudinal studies, and we can encourage independent investigators to retrospectively analyze existing data on integrative therapies. Along these lines, NCI has their best-case series on treatments for cancer patients.
In general, it is logical to test substances, be they nutrients or phytochemicals, in cell culture and animal models before you proceed to clinical trials. There are benefits to studying animal models: there is less genetic variation and less variability, and animal testing spares the inconvenience, expense, and discomfort of a clinical trial. Samples can be easily obtained for intermediate markers. There are more humane ways to do animal research at this time. However, the downside is that a treatment that is effective in an animal may not work in a human. It is often unclear whether this is a species-specific variation or whether the humans may be "blocked" in their healing process by the status of their immune system, their belief systems, or intentionality. Vickers: The value of different study designs cannot be assessed separately from the questions they ask. In this sense, a small exploratory study is no better or worse than a large randomized trial. One cannot assess the "relative value" of different designs anymore than one can compare the relative value of a cucumber and a zucchini.
Burns:
The comment I would like to make here is that it is possible to do very high-quality research with modest funding. A prime example is the Chinese medicineherb trial of irritable bowel syndrome (IBS) that was recently conducted. The study compared patients randomly assigned to placebo versus patients assigned to the standardized herbal formula. After 6 months, the 2 groups crossed over, so that the groups were now allocated as follows: placebo, standardized formula, and formula by diagnosis. Patients were then followed to see how they did in terms of IBS. Those who received the formula had significantly better outcomes compared to the placebo, but the group that received the individualized formula did even better. The bigger issue is that we tend to get caught in all the early components of research, such as how do we recruit people and is there going to be toxicity, when these are agents or modalities that are already in widespread use. Patients are taking these agents on their own because the margins of safety are quite substantial. When you are doing a phase I trial with herbs or other relatively nontoxic modalities, then we should bypass the phase I trial because it is really a waste of money. Funding is also wasted when it focuses on which agents or compounds are going to be most effective, and we try to break it down. This does not work in the context of TCM.
More recently, we have seen a great deal of attention focused on the potential adverse interactions between herbal agents and conventional drugs. For example, we know that St. John's Wort may affect the effectiveness of various chemotherapy drugs. Many recent discussions have highlighted potential herbal interactions with adjuvant treatment using hormonal drugs such as tamoxifen. Gleevec and other anticancer agents now have warnings on the label concerning herbal agents. Research needs to look not only at drug-herb interactions but also at drug-drug interactions, and I am sure there are plenty of examples whereby those interactions occur yet have not been adequately investigated. Dobs: This is a considerable problem. RCTs involve immense cost. Any good trial requires a great deal of detailed work to ensure that the right population is recruited into the study. This, in turn, means hiring many personnel to carry out the recruitment and to help coordinate and run the study. It means giving a great deal of attention to the specifics of the intervention and to standardizing interventions, outcome measures, and laboratory assays, many of which are fairly experimental. The solution is to vary the types of studies because some study designs will be less expensive than others. The most expensive study is generally a long-term clinical trial in which patients are randomized to various interventions and followed for long periods of time. Nonetheless, there is another kind of study that can be less expensive. This would be a cohort study, an observational study in which you simply follow patients over time with a medical problem. You look at which patients are using CAM interventions and how they do with those interventions compared to patients who use only conventional treatments.
Observational studies such as these do not provide the kind of rigorous data you get from a clinical trial,
The lower levels of evidence provided by the retrospective studies are still of course valid investments of our resources, simply because we need whatever information we can get on integrative cancer therapies. This is true for 3 reasons: first, because the CAM therapies or agents might be helping people; second, the CAM intervention may confer no benefit and thus may be a complete waste of money; and third, the CAM intervention may actually be doing some harm, perhaps either promoting disease or reducing the effectiveness of conventional treatment.
Question 3.
In approaching research on integrative care, should we study the separate interventions (eg, acupuncture, Boswellia, massage, journaling) in great detail and attempt to resynthesize integrative cancer care on the basis of fully validated CAM therapies? Or should we study the existing systems of full integrative care that are already in use in the community-based oncologic setting?
Hess: Both types of approaches should be used. There are certainly several reputable organizations, centers, and academic institutions that are pursuing integrative models of cancer care. These programs should be evaluated to determine which components of the programs are believed to work or not work based on feedback from staff, physicians, patients, and cancer patient support personnel. This input would be valuable to determine what needs are being met, what areas need to be improved, and what therapies actually may be effective. We have only begun to study certain CAM approaches that have been introduced in recent years. In some cases, these new CAM therapies may need to be tested separately, perhaps in pilot or preclinical studies, before integration is initiated. Cohen: There is an argument for both types of study depending on the problem. Studying single-modality therapies is very useful and appropriate only if the particular modality completely treats the problem or if a single agent or therapy is thought to produce considerable benefit on its own, perhaps based on empirical evidence. An example is the use of ginger or acupuncture for nausea. In this example, testing a panel of therapies would be overkill. On the other hand, studying a panel of well-validated CAM treatments might help lay the foundation for a reasonable, integrative treatment protocol. It is useful to study existing systems of cancer care in relation to survival since each individual therapy may not work on its own. The integrative approach is often the approach that leads to maximum benefit in the context of chronic, multifactorial diseases such as cancer. To improve cancer survivorship, a patient may need to have surgery, receive nutritional and herbal therapies, undergo cognitive restructuring, pray, and attend a support group. The system of treatment is more powerful than any of the individual components within the treatment. Vickers: There is no either/or here: you can do both. I think it is a good idea, in general, for different elements of a CAM program to be assessed individually.
But that is not to stop someone from assessing a whole program if they want. There are all sorts of questions worth asking. Some CAM advocates are extremely idealogical: they have firm views of what constitutes "real" integrative care and disparage other models. To me, this is absurdly parochial, but it is behind some calls that we should evaluate only "whole systems" of CAM. Another issue here is that it is not always essential to assess everything. Elsewhere, I have written that we probably do not need research on aromatherapy (the practice of adding aromatic oils to the lubricant used in massage) 8 any more than we need research on, say, whether having a pleasant environment with nice pictures on the wall helps psychotherapy. Burns: We can study them one way, but we have to ask ourselves continually, "How are people going to use these agents and modalities? Are they going to be used separately or within a system?" In evaluating the efficacy of TCM, it is obviously a system of treatment that needs to be studied. That, obviously, is my bias. We often see these studies framed in terms of complementary approach: TCM is used in conjunction with conventional treatment.
In terms of studying TCM or naturopathy as a system versus individual components of these systems, there are too many overlapping and interacting components within each system. It is very difficult to tease out which component may have a therapeutic effect. Within the 2 large "alternative" systems such as TCM or naturopathy, there are different diagnostic criteria, but the treatments are used similarly. Which piece is treatment, and which piece is an interaction? The goal of TCM is to always have synergy, whereas this is rarely if ever an expressed goal of conventional medicine. Dobs: We need to study both the separate CAM interventions and the full systems within CAM. If it is possible to separate one intervention for research purposes, such as studying a particular form of massage therapy or a dietary supplement, certainly that should be done. Nonetheless, this is often not relevant to the integrative medicine setting, in which people are typically using multiple interventions. There is the very real likelihood of interactions between different interventions, whereby a natural agent that improves circulation, for example, might also enhance the benefits of massage. It is possible to set up a clinical trial to evaluate multiple interventions in aggregate. When you have only 1 variable, you generally need a smaller sample of patients enrolled in the study. You can then get very useful information about that particular intervention, such as massage or acupuncture therapy. If you are looking at a systems-based approach, you need a larger sample size to have adequate statistical power. You will need to establish standardization of, say, 5 different interventions, as opposed to the 1 intervention, such as massage therapy. Such a study will be considerably more expensive.
The point is that we do want to do something that is realistic. If we come out and say that massage therapy does not work, one might then say, "Well, no one is doing massage therapy alone, they're doing it in combination with 1 or 2 other things." Massage may be one of the essential links within a broader, integrated treatment context. By itself, it may not appear to have much value, but when included as part of a larger system, its role may be invaluable.
Question 4.
Most dietary and botanical supplements are natural agents; many of these have been used by human populations for centuries and can thus be assumed to have a high level of safety. As nonpatentable agents, they are unlikely to receive large amounts of funding from pharmaceutical companies. Is it really necessary or practical to conduct full examinations of these agents (or combinations of herbs and conventional agents) using the phase 1-phase IIphase III model used in testing new drugs and drug combinations?
Hess: We need to be smart in how we proceed in this area.
While grant dollars are tight for research studies, there is an increased need to evaluate safety and efficacy. We may need to pool the knowledge we have gained from the history of medicinal use of many of the botanical agents and then use this as a basis for the development of trials. In many cases, phase I trials could be bypassed by looking at safety data from the European experience with many herbal agents; however, we should require phase I, II, or III testing for any new botanical agent. The most critical aspect of these studies is to look at the combined effects of botanicals and conventional cancer drugs. This point has already been proven with studies with St. John's Wort and Irinotecan. In addition, many other herbs/supplements have shown adverse effects in the liver, kidneys, on hormone levels and on the cardiovascular system. Another point is that we need to know what we are testing is the same agent and that it contains those active ingredients we believe are required to achieve a particular therapeutic effect. Cohen: Yes, it is necessary to conduct full examinations of herbal agents because it is important to know the safety and efficacy of the products. In addition, patients may use herbal remedies in combination with traditional remedies (some patients are on dozens of prescription medications). In the past, the herbalist grew the herbs, prepared and dispensed them, and then followed up on the treatment. Since resources are limited, we will have to prioritize which products must be studied. Perhaps some of the preliminary research can be done on animals or outcome studies. Vickers: The answer to this question depends on whether you are a CAM advocate, and wish to protect and promote CAM wherever possible, or are genuinely interested in finding out what is best for all cancer patients. If you are a CAM advocate, by all means feel free to engage in special pleading as to why research is not really necessary for CAM. If your prime interest is the well-being of cancer patients, now and in the future and throughout the world, you probably want to know whether a therapy does more good than harm. In general, this means a phase III trial. But before we go forward to a time-consuming and expensive phase III trial, it is generally a good idea to do a smaller phase II trial to evaluate the chance that you have a useful intervention (on the same principle that it is useful to go on a few dates before deciding to get married). And before phase II, you are going to want an idea of the best dose and formulation to use. This is not just a question of safety, although that is important too: one of the "natural" agents tested at MSKCC and that has been used by "human populations for centuries" and available on the health food store shelf turned out to cause a quite severe (though fortunately reversible) toxicity when given to very sick children with advanced cancer. This illustrates an important point: just because something is safe in general public use does not mean it is safe when given to cancer patients, who generally have comorbidities and are on concurrent treatment. The main reason to do a phase I is to work out the best dose. We are doing 2 phase I trials in which we are taking bloods from patients on different doses to work out which dose is likely to be most effective. Incidentally, doing phase I and phase II trials is probably in CAM's best interest. Look at vitamin C: they did a big negative trial, and the advocates said, "Oh, you used the wrong population." Then they did another trial, and people nowadays are saying that IV rather than oral ascorbate should have been used. It is exactly these sorts of issues concerning dose and patient group that can be worked out in early phase research. On a final note, there is nothing written in stone about the design of phase I and phase II trials. Phase I trials do not have to escalate to a maximum-tolerated dose, and phase II trials do not have to measure tumor regression. Researchers working with vaccines and so on do not use such designs blindly; the same should go for CAM.
Burns: I do not think it is necessary or practical to conduct full-scale clinical trial testing of these agents. We can easily do laboratory work to identify purity and potency of these agents and then go from there. This is particularly important if patients are starting the trial with metastatic disease. In such cases, we do not have the time to go through the first few phases, and it is tragically unfair to the patients to subject them to these phases if we have a strong body of empirical and preclinical data demonstrating safety. In addition, if we are measuring functional outcomes such as energy levels, mobility, or inflammation, we should not need those other phases. Many of the studies of conventional medicine are not interested in these functional markers or quality-of-life outcomes, and yet they are critical outcomes. By the same token, many of the conventional markers are in fact not a good fit for the kinds of changes elicited by TCM. I think TCM in general may be better measured by quality-of-life outcomes; these outcomes are entirely complementary to the conventional markers of disease.
I would like to see more quality-of-life studies done of TCM for early-stage breast cancer and other cancers. At the same time, we can study drug-herb interactions such as those involving tamoxifen and various estrogen-modulating herbs. The bottom line here is that when the focus is more quality-of-life oriented, as would be possible with early-stage disease, we do not and should not require the 3-phase approach. Dobs: I believe that they should be tested, just as we expect testing from any pharmaceutical product. It is tough when you have something that you can buy in the drug store or even the grocery story, and yet when you do research on it, there are various levels of regulations imposed on your research. So let us say you have an agent that is already widely used, perhaps by tens of thousands of people, yet the Food and Drug Administration (FDA) still requires that you run a phase I study on the same product. It is easy to say that this does not make sense when you have an agent you know is quite safe. Nevertheless, the government and research regulatory agencies we deal with are under increased scrutiny. When something is given as part of a research protocol, it has to be held to a higher standard than if someone walks into a health food store and buys it for their own use. With the 3-phase clinical trial model, we are being forced to do the same thing with dietary supplements that we do with drugs but only when a therapeutic claim is made with regard to a particular disease or medical condition. The FDA has made that distinction about therapeutic claims, and there are many reasons why it is reasonable. Most important, if we are dealing with a diseased population in which there is a chance that the dietary supplement may in fact abet the disease as opposed to helping the person, then we have to play by the rules and go through the 3 phases of clinical trial testing. In general, if I have any question regarding a research issue, I will always check it out first with the FDA.
Question 5.
Given the very large number of dietary and botanical supplements currently in use among cancer patients, can you suggest other experimental or nonexperimental models for exploring the potential usefulness of herbs, vitamins, and other supplements in integrative cancer care? Please be specific in your answer and provide examples to help illustrate your suggestions.
Hess: Basic science still has an important role to play in the study of potential therapeutic applications of supplements. I believe animal models may represent an as-yet untapped experimental approach, particularly when looking at the effects of dietary and herbal supplements in combination with radiation and traditional chemotherapy. While there may be some differences in the cytochrome P450 systems of different animal models, I believe this combination approach would be worthwhile along with pursuing additional in vitro data in this area. Additional studies could also be pursued in terms of chemoprevention studies in animals with various herbs. Finally, testing whole plants, as opposed to a particular activity of a plant, should also be explored. In the case of therapeuticgrade essential oils, an oil may have between 200 and 1000 chemical constituent peaks, each working synergistically to balance the organism. Can we see a better efficacy if we use the whole plant compared to a compound identified in the oil? Those kinds of questions remain to be answered. Cohen: Supplements can be tested initially in cell culture and animals models of cancer. If it does not work in animal models, it is unlikely to work in humans. We can document outcomes of herbs in patients that are already being treated by their practitioner. Another avenue that holistic practitioners use is the use of specialized biofeedback machines placed on acupuncture meridians to test for appropriateness of natural products and homeopathy. Further experimentation is needed to demonstrate validity and reliability of these types of machines before incorporating them into comprehensive cancer care.
It is important to emphasize that individualization can be incorporated into the design of the randomized trials. For example, in an Ayurvedic study with a specific agent, the patient could be diagnosed by dosha prior to randomization, and then the randomization could be stratified by dosha. Subgroup analyses could be performed at the end of the study. Alternatively, the RCT might allow for individualized assessment and treatment for the disease in one of the arms of the study. This was done successfully in a study on TCM for IBS that was published in a 1998 issue of the Journal of the American Medical Association. This is a great model for further studies of individualized treatments.
Vickers:
Other than what? To sum up my views on this topic: let's avoid the ghetto. I have yet to see a case in which a completely new methodology has to be invented to answer a question just because we are investigating CAM. Any therapy has special features that need to be taken into account when it is researched, requiring a certain degree of modification of research designs. Burns: We have a number of centers in the Bay Area where cancer patients are being treated. We were able to develop a protocol that was multiarmed, so that we all agreed on the same 6 diagnoses, and within those 6 diagnoses, we set up a treatment arm with 7 primary points and 5 variable points, and we similarly have an approved herbalist. This is somewhat limited. It is not the exact way we do things in real life, but it does provide a much wider scope that still enables us to evaluate the treatment. We would potentially generate some very important information from this kind of study because it would eliminate practitioner bias, and we would be able to see the treatment line up with the diagnosis, and we would have individualized treatment but without a lot of variability. We can do both quantitative and qualitative measures, but such a study could obviously take years. First, we would have to determine whether we can enroll people for the study; do they drop out similarly across the board, and are they tolerating the prescribed herbs? Do we have to change them as a group? We then have the treatment arm choices evaluated independently by other providers. We then have other people in the field do a review list to determine which herbs should be included in the study. This way, we establish a consensus among experts in the field to devise an optimal protocol. Let's say we did this in the Bay Area and we had 3 providers giving the treatment within the trial. Perhaps we could have 1 provider doing the initial intake so that only 1 person is seeing everyone initially. This way, the diagnosis is appropriate and correct, and there will be more internal consistency.
Unless we actually try these more innovative designs for interventional research, we will never know whether they work or not. Certainly, some interventional research focus is needed. If we simply do retrospective observational studies, I do not think the medical establishment will value the information. (On the other hand, patients who embrace CAM therapies will definitely listen to that information. In general, I find that people who embrace CAM therapies are willing to make claims that go far beyond what would be deemed acceptable from an evidence-based medicine point of view.) Last, patients who are included in studies that combine CAM therapies with conventional treatment have very advanced cancers, and their quality of life has already been markedly diminished by the conventional treatments they have received. At this point, it may be difficult to see the quality-of-life benefits of CAM approaches. Again, I would like to see more studies of integrative therapies done in the early stages of malignant disease. Survival is important, but more attention needs to be focused on quality-of-life outcomes when it comes to evaluating the benefits of herbs, nutrients, or other types of supplements. Dobs: Observational studies such as case-control studies and retrospective cohort studies are not ideal, but they have been used successfully for the investigation of other kinds of medical problems. Keep in mind that with the first studies on the cancer-related effects of smoking, we did not have RCTs. We did not take a group of people and randomly assign them to a smoking group versus a control group to see which one developed lung cancer. The conclusions were based on retrospective data, to see who was smoking and how long they smoked, before determining who developed cancer and what types of cancer they developed. Again, I think we might do something similar in the CAM arena as well. Simply recruit a group of cancer patients to see who is using CAM therapies, then measure their survival and compare this group to a matched group of cancer patients who did not receive CAM therapies.
We are presently doing a study of soy protein in postmenopausal women to see what the benefits may be. We are looking at quality of life and functional status. In a separate study, we are using a fish oil product to see if it may help pancreatic cancer patients gain weight. We are not talking about the underlying pancreatic disease but instead an important process associated with this cancer (weight loss), which is highly correlated with survival. We have 60 pancreatic cancer patients in this study. One group is being randomized to fish oil, a standardized product recommended by the NIH (from a company called Incell), and the other group to a placebo. The primary outcome measures are weight and body composition, and we are also looking at neuroendocrine, immunological, and inflammatory markers. These kinds of studies can be quite helpful. Intermediate endpoints, such as weight loss, have profound prognostic value, and thus such research is immensely relevant to the further development of cancer medicine.
Summary and Discussion
Shortened versions of each of the questions precede discussion sections.
Question 1.
Can integrative therapies be adequately studied with randomized controlled trials?
Response
One of the scientists that we approached about responding to this series of questions about the problems of designing RCTs in integrative medicine opined that it would be very difficult to find anyone to argue against RCTs. However, the emerging field of integrative cancer care is sometimes surprising, and we found that the opposite was the case. Some of our respondents strongly criticized the use of RCTs in integrative care. The thoughtful discussions of practicality and proper design raised by these critics are impressive and worth attention. These critics of the RCT point out areas in which the research community may need, at the least, to be more cautious in the prioritization of research agendas relating to integrative therapies and certainly to be more selective and careful in the design of RCTs.
Dr Suzanne Hess is blunt in her assessment of the current impracticality of studying integrative therapy with RCTs. She points out the difficulties in recruitment of patients, certainly a prime consideration in the design of any RCT. The percentage of patients participating in clinical trials is startlingly small to begin with, and trials on integrative therapies must compete with the vast array of clinical trials of conventional cancer therapies. An additional problem is that integrative therapy trials often rely on conventional health professionals to recruit patients for trials. Conventional practitioners may engage in "gate-keeping," refraining from referring patients to trials of integrative therapies, as CAM investigators have found out in attempting to execute studies in the recent past. 9 These and other difficulties may lead to the inadequately powered studies of CAM therapies that Hess observes in the literature. All of the points raised by Hess can, in the long run, be addressed. This can be done through collaboration with scientists experienced in clinical trial design and through provision of more training to the community of CAM investigators in the practicalities of designing trials.
Hess also raises questions regarding the endpoints that are chosen for RCTs in integrative medicine. She asserts that CAM practitioners may not aim to extend survival but rather focus on improving quality of life. We would concur with this for many of the specific CAM techniques that can make up an integrative medicine intervention and certainly agree with the importance of carrying out research on quality of life in cancer patients. With an optimally designed trial that uses some of the many instruments that have been designed for measurement of quality of life, however, this endpoint could be as effectively studied in RCTs as in other types of designs.
Dr Cohen raises another set of problems with RCTs, including generalizability and distortion of normal CAM protocols in the interests of conforming to the rigidity of the clinical trial setting. She also addresses the issue of nonspecific effects, such as of the presence of a therapist. These are all issues that can be handled with appropriate choices of trial designs, but additional attention needs to be given to some of them, particularly nonspecific effects. One example of a study that attempted to control for nonspecific effects was an investigation of the efficacy of massage and Healing Touch in controlling anxiety and related variables in cancer patients by Post-White and colleagues. 10 In this study, patients were randomly assigned to receive massage, Healing Touch, or control treatments on different weeks of their chemotherapy treatments. To control for the presence of the therapist-a nonspecific effect-one of the control conditions included the patient simply resting while the therapist stayed in the room as a companion. This is just one way that nonspecific effects might be studied. Cohen advocates more detailed exploration of the CAM endpoints valued by patients and practitioners. This is an area in which qualitative research may lead to the elucidation of new variables that are of special interest in the evaluation of integrative care.
Dr Andrew Vickers has a no-nonsense approach to the problems of designing randomized trials that deal with a variety of endpoints and individualization of treatment plans. Dr Vickers has an interesting research background not mentioned in his introductory biography. He has published several randomized trials in the area of homeopathy 11 as well as acupuncture and music therapy. 12 Homeopathy is an area that depends on individualization in the prescription of remedies, and Vickers is thus in a good position to comment on problems of individualization. Several of Vickers's publications constitute excellent resources for those interested in the design of clinical trials in alternative medicine, including discussions of how to decrease the number of subjects needed in clinical trials and in what situations the use of placebo treatments for control groups may be irrelevant to clinical decision making or overly burdensome. 13, 14 He has also provided useful discussions of the distortion of nonspecific treatment effects caused by the use of a placebo for the control group, as mentioned by Cohen, and on how to work around this problem in trial design. 15 Dr Vickers criticizes the concept of the need for studying endpoints considered relevant by CAM practitioners. While such studies are controversial, as he notes, cancer patients are nevertheless "voting with their feet" and frequently paying out of pocket in an effort to obtain what CAM practitioners offer, and the endpoints these practitioners feel are important may be an important part of their overall impact on patients. While I think it is critical to use existing validated instruments in studying most endpoints and it is very relevant to explore what patients think they are receiving from CAM therapies as a basis for studying other endpoints, I think that closer attention to at least some of the endpoints considered important by practitioners may result in interesting findings. 16 Knowing the true goals of the CAM practitioners, in the context of their treatment philosophies, may also help us to design trials that better assess their potential benefits for patients. Ms Beverly Burns responds to this question as a clinician, specifically, an acupuncturist. She usefully distinguishes settings in which relatively straightforward problems are studied, which can be treated with a single modality, a situation in which it is relatively easy to design RCTs, from the setting in which a systemic illness is treated with an entire system of medicine. It is certainly possible to design randomized trials to study whole systems in this way, but Burns is right to raise the danger of reductionism when she compares the interpretation and management of such whole-system trials with the study of herbal medicine, which does frequently lead to an overemphasis on isolation of single active compounds. This is especially true in a field in which relatively little is known about the components and interactions of multiple interventions.
Dr Adrian Dobs insightfully compares the study of multifaceted CAM interventions to the study of conventional interventions that involve multiple treatments, such as the overall management of diabetes. Like integrative care, modern diabetes management includes not only drug administration but also nutrition, exercise, and other interventions. Recent clinical trials have studied entire interventions rather than isolated parts, an encouraging development. While it is true that more is known about the conventional interventions that make up diabetes management, trials of this sort may indeed provide models for the design of RCTs in integrative care. Dobs also points out the flexibility that is sometimes built into conventional drug trials, where dosage regimens may be changed to suit the individual needs of patients but can still stay within the parameters of a particular treatment arm in the trial. The ability to incorporate such compromises into clinical trial design suggests that flexibility and balance in setting up trials of multifaceted interventions such as those of integrative cancer care may result in successful and reasonably realistic study designs.
I would raise one further issue not discussed here by any of the panelists: the difficulty of having a true control group for an integrative medicine RCT at a time when a large proportion of cancer patients are pursuing integrative interventions on their own without telling their physicians. Would cancer patients who agreed to be randomized to a control group in a trial of integrative medicine actually refrain from using any integrative techniques? And if they did use such techniques, would they reveal them to investigators running the trials? If both the experimental and the control groups are using integrative techniques (one as prescribed and one in an unmonitored fashion), our ability to find statistically significant differences may drop. As more and more patients use integrative care, the number who would actually adhere to control instructions not to use techniques other than those prescribed in their treatment arm may grow smaller and smaller. Accomodating this situation by designing control arms that include some integrative interventions, or sham versions of such interventions, may provide a way out of this dilemma.
Question 2.
How can financial resources best be allocated in the development of useful bodies of information on CAM?
The response of Dr Hess demonstrates a concern for disseminating the results of existing research on CAM and integrative care in cancer to the medical community and to patients. It is encouraging to note that despite the sheer mass of possible research questions in this area, progress is indeed being made. Making practitioners aware of this progress and of findings encouraging as well as discouraging the use of particular interventions is certainly something that needs to be attended to. I strongly support her point about the distribution of hard-copy information for patients in multiple languages to be distributed at cancer centers. While several Internet databases have sprung up that provide reputable information on CAM and cancer, the patient population that needs this information does not always have good Internet access or the facility in English needed to use it.
Dr Cohen discusses this question from the point of view of allocation of research funds. She emphasizes the need to control the costs of research by prioritizing and triaging the various treatments competing for funds by performing preliminary studies. A large-scale randomized trial represents a substantial commitment of funds, patient participants, and time.
In an area that is not (or not yet) driven by pharmaceutical company funding, it is necessary to ensure that such commitments are made mostly to studies that have the potential to affect clinical practice directly. Cohen mentions exploring the use of in vitro and animal models and outcomes research in focusing the research efforts of the community. Her suggestions emphasize the genuine importance of designs other than RCTs at this point in the development of research on integrative cancer care.
Dr Vickers points out that the value of a research design depends on the question that is being asked. In fact, it is precisely a greater focus on attempting to figure out what research questions are of the highest priority that will help to determine how best to allocate research funds and whether RCTs are the best use of those funds at this time.
Ms Burns suggests that not all RCTs need to be extremely costly and asserts that it would be feasible to deemphasize funding for phase I-type testing because of wide use of many agents that are felt to be safe after centuries of traditional use. She also asserts the value of studying herbal components as part of their traditional formulas, rather than breaking them down. She does feel that looking at drug-herb interactions would be useful, comparing them to drug-drug interactions. I must admit that I find the amount of anxiety (and publicity) that has attended the discovery of drugherb interactions curious. Herbs are drugs-the original drugs, in fact-and are bound to have interactions with other drugs, especially when they are used as high-dose single-herb preparations. The medical profession does not sound alarm bells, hold press conferences, or call for entire classes of drugs to be removed from the market when a new drug-drug interaction is found. They simply study the clinical significance of the interactions (not all drug interactions are clinically significant) and, when needed, provide warnings to avoid combining the 2 agents. 17 Herb-drug interactions should be treated in the same way. With only rare exceptions, the apparent panic with which some parties are viewing them is unnecessary.
Dr Dobs focuses more on the use of specific study designs that are less expensive than RCTs but still provide important basic data on CAM and integrative medicine: prospective and retrospective cohort studies and case-control studies. These studies, besides providing information on practices about which little is known but that may have substantial positive or negative impact on patients, can also help in the design of future RCTs and the prioritization of areas of study for RCTs. The value of these study designs at this time in the development of integrative care should not be overlooked in the quest to gain a better reputation as an evidence-based practice: they may provide one of the quickest routes to developing a useful database of information on integrative care.
Question 3.
Should separate CAM integrations be studied and then be synthesized into new models of integrative care? Or should existing full systems of integrative care already in use be studied?
Dr Hess sensibly advocates each of these approaches, as indeed do all the respondents. She proposes a practical strategy for picking out specific areas for detailed scientific study-prioritization by program evaluation based on feedback from the various parties concerned with what seems to work and what does not. Cohen raises the issue of synergism in discussing trials of whole systems, though acknowledging the practical potential for treatment systems assembled from wellvalidated CAM treatments. One additional difficulty of evaluating full systems of therapy as if they were comparable to conventional treatments is that traditional health systems and conventional Western medicine are grounded in different philosophies of health and illness. These result in disparate diagnostic categories as well as different treatments and expected outcomes. Vickers advocates what appears to be a more "commonsense" approach to determining which research questions ought to be asked. Just because RCTs may be rather easy to design and execute for some particular type of therapy does not mean that large numbers of trials in that area need to be funded. Therapies that appear to have the potential to add relatively little to the lives of patients and that do not pose clinical dangers should, in his view, receive reduced levels of funding. Burns comes out squarely on the side of studying whole, existing systems of care such as TCM or naturopathy. A basic goal of some of these systems of care is to foster synergies, and the idea that one could develop similarly sophisticated systems by simply assembling the results of a variety of randomized trials on different therapeutic modalities overlooks the wisdom that results from decades, or centuries, of practice. Dobs emphasizes the tension between the greater expense that might pertain to RCTs of systems-based approaches, which need large patient populations and a greater effort in standardization of multiple regimens, and the real need to design studies that are truly representative of what happens in clinical practice.
Question 4.
Is it necessary or practical to conduct full examinations of botanical and dietary supplements that have been used for centuries (or combinations of herbs and conventional agents) using the phase I-II-III model used in testing new drugs and drug combinations?
We raise this question because of the problem facing the integrative practitioner and the patient in sorting through the diversity of herbs and dietary supplements that may be useful for cancer care or are advocated for cancer care by various practitioners. There is a great deal of published information on herbal medicines, and many randomized trials have been done on the major herbs but few specifically in the area of cancer care. Every year, our cancer patients bring us new supplements being marketed as cancer cures, or the "most powerful of any antioxidant," and want to know why we are not recommending these agents in our clinics. As acknowledged by our respondents, there are also problems in the area of quality control in some herbs and of exactly which herbal preparations are most active and appropriate for different conditions. From the clinical viewpoint, it would be useful to have recourse to some site providing accessible information on these little-known agents while we are waiting for the full-scale randomized trials to be completed (or started). This would allow clinicians to provide patients with reasonable answers about the usefulness of supplements and make decisions about what agents might be worth including in clinical protocols.
Some of our respondents point out areas or methods for prioritization of studies in this area as a possible solution for this relevant problem. Dr Hess points to a vital need to catalog potential drug-supplement interactions. Dr Cohen mentions prioritization by animal models or outcomes studies. She also raises the issue of the practice of traditional herbalists using multicomponent prescriptions. To the extent that these are standardized formulas, such as the traditional Japanese formula Sho-Saiko-To, research on this area is fairly easy to formulate. Studies of individually prescribed multicomponent formulas can certainly be designed, although they tend to raise many questions about the activities of the individual herbal components and to be difficult for those trained in conventional pharmacology to interpret. Ms Burns does not see the usefulness of early-phase studies, especially in quality-of-life-oriented studies. She also raises an important ethical point for studies of patients with metastatic cancer: do we have time to wait for all the drug development stages to be completed before we make an assessment of whether traditional treatments with an empirical background of safety are acceptable for use in the cancer setting? This seems a reasonable question, and especially with situations concerned with quality of life, perhaps safety would be an adequate basis for use until research can be conducted to determine whether treatments are effective in prolonging life. Finally, Dr Dobs advocates following the 3-phase model for the extremely practical reason that without it, herbs and supplements will never obtain full scientific credibility, much less authorization from the FDA.
Dr Vickers notes that CAM advocates may claim that research is unnecessary on their techniques. While this has not been our collective experience with most CAM practitioners, there are certainly areas of CAM, and medical care in general, such as proper sleep hygiene and sensible physical fitness routines, that common sense and previous research suggest are basic good health practices that should be implemented with any patient who is experiencing a severe illness without waiting for RCTs and meta-analyses. 8 With little or nothing in the way of adverse effects, there seems to be little reason why research on such techniques needs to be conducted prior to making them part of an integrative regimen. In the long term, it may be valuable to research their specific impact on cancer populations, but these studies may not be as high a priority for research funding as some other areas. As the many questions raised by our panel in this article show, there are serious questions about what types of studies ought to be done on CAM at this time and a strong awareness that the design of RCTs in integrative cancer care needs to be done very thoughtfully. I fully concur with Dr Vickers that the use of herbs and supplements by cancer patients, with their many comorbidities, raises questions even about herbs widely regarded as safe and needs close study.
Dr Vickers also raises the very important point that phase I and phase II studies are actually vital to the enterprise of efficacy research since without them, we run the risk of studying the wrong formulation, dosage, route of administration, or patient population. A study that is flawed because of 1 of these factors may give negative results for an agent that is actually quite valuable. It is clear in many early and some recent studies of herbal medicines (eg, some studies of the use of echinacea in colds) that the product selected for testing was probably inappropriate and unlikely to contain active compounds. Despite the fact that I would like to see RCTs provide a strong evidence base for integrative care, I think it could be argued that for the present, we actually need more phase I or early phase II studies elucidating the best preparations for clinical use, the incidence of side effects and drug interactions, and the proper means for standardizing interventions in whole-systems studies. Obtaining basic data on safety and dosage in cancer patients undergoing therapy may be among the most important next moves. Supplementing these detailed studies with outcomes studies of the sorts mentioned by Drs Cohen and Dobs could provide at least some short-term data on efficacy as well as more solid data to assist in determining what systems should later be the subject of RCTs. What is concerning about this argument is the large number of herbs and supplements and their combination with the great number of cancer-related conditions and chemotherapy protocols (even if we are able to meaningfully exclude the combinations that could be projected to have herbdrug interactions). The prospect of recruiting enough patients for all these trials, much less recruiting enough funding, is dubious. Given sufficient time, funding, and recruitment, however, this may be a practical way to proceed while other systems of evaluation continue to evolve.
Question 5.
Can you suggest either experimental or nonexperimental models for exploring the potential use of herbs, vitamins, or other supplements in cancer care? Provide examples.
Dr Hess points out the use of animal models to screen natural agents as a way to focus our efforts on a more manageable number of trials, as does Dr Cohen. Cohen also points to the use of outcome studies. Dr Vickers adheres to traditional research methods. Burns proposes a complex trial design that could be rather difficult to carry out but is clearly an attempt to place the inherent diversity and flexibility of the traditional Chinese system of herbal treatments in a context in which a scientific study could be done in a community-based setting. Dr Dobs, always helpfully practical and balanced in her responses to these questions, again points out the usefulness of observational studies and emphasizes their importance in the history of other areas of inquiry. She also points out the value of using intermediate endpoints that are correlated with survival, rather than survival as a major outcome variable, thus decreasing the time and expense of studies in several natural agents.
In reflecting on the responses to this set of questions, I find myself impressed by several specific points. First, it is certainly possible to use the RCT on the wide variety of natural agents and integrative treatment systems. There are, however, many obstacles to overcome in designing these trials so that they answer the questions that we most need to explore and so that they are successfully carried out from the recruitment to the analysis phases. I think we will continue to see good RCTs carried out on selected elements of the wide variety of CAM interventions that are part of integrative care as more investigators become inspired to pursue these treatment modalities. But as much as we all would like to have the credibility that RCTs offer, I think we still need to do a great deal more preliminary work in evaluating treatment systems using observational designs and outcome studies so that we know which systems and settings will be best for performing the RCTs. Further preliminary work is also needed to select the right supplemental agents and formulations to ensure that the agents put into the clinical trial process are capable of producing in the clinical trial setting the results seen in practice. Having the data from phase I and II studies and from observational and outcome studies will give us a better level of knowledge to proceed in our clinical practices, as well as the assurance that when we do come to the point of doing more RCTs, our efforts will not be sabotaged by poorly conceived trials that may obscure, rather than illuminate, the benefits that so many patients are searching for, and often finding, in integrative cancer care today.
